CN114886895B - Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B - Google Patents

Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B Download PDF

Info

Publication number
CN114886895B
CN114886895B CN202210576920.2A CN202210576920A CN114886895B CN 114886895 B CN114886895 B CN 114886895B CN 202210576920 A CN202210576920 A CN 202210576920A CN 114886895 B CN114886895 B CN 114886895B
Authority
CN
China
Prior art keywords
bay87
medicament
hepatitis
hbv
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210576920.2A
Other languages
Chinese (zh)
Other versions
CN114886895A (en
Inventor
林永
黄爱龙
毛彬力
邓莹莹
魏真
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Medical University
Original Assignee
Chongqing Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Medical University filed Critical Chongqing Medical University
Publication of CN114886895A publication Critical patent/CN114886895A/en
Application granted granted Critical
Publication of CN114886895B publication Critical patent/CN114886895B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides an application of a small molecule inhibitor BAY87-2243 in preparing a medicament for treating hepatitis B virus infection. The invention uses different liver cancer cell lines which can stably produce Hepatitis B Virus (HBV) or HBV-infected human primary liver cells to verify that BAY87-2243 can obviously inhibit HBV transcription and replication and effectively reduce cccDNA expression level through the in vitro treatment of BAY87-2243 with different concentrations.

Description

Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B
Technical Field
The invention relates to application of a small molecule inhibitor BAY87-2243 in preparing a medicament for treating hepatitis B
Background
Viral hepatitis B (viral hepatitis type B) is an infectious disease mainly caused by Hepatitis B Virus (HBV) and characterized by liver disease. Clinically, the symptoms of anorexia, nausea, epigastric discomfort, liver pain and hypodynamia are mainly manifested. Some patients may have jaundice fever and hepatomegaly with impaired liver function. Some patients can become chronic, even develop cirrhosis of the liver, and a few can develop liver cancer.
At present, the effect of treating chronic HBV infection by nucleoside (acid) analogues and interferon is very limited, and only a few patients can realize 'functional cure'. The key to cure chronic hepatitis B virus infection is that covalently closed circular DNA (cccDNA) in host hepatocytes must be thoroughly eliminated, and the cccDNA is a template for HBV transcription replication and a viral gene repository and is also a key cause for relapse after drug withdrawal of patients with chronic hepatitis B. At present, the medicine for effectively removing cccDNA is still lacking clinically, so the search and development of the medicine for effectively removing the hepatitis B virus cccDNA have good clinical application prospects.
The small molecule inhibitor BAY87-2243 is a potent selective hypoxia-inhibitor factor-1 (HIF-1) inhibitor. At present, research reports show that the compounds can inhibit tumor cell proliferation by interfering mitochondrial function, can be used for treating cancers such as lung cancer, also report research that the compounds have positive influence on Intestinal Mucosa Barrier (IMB) function, and can be used for treating sepsis. No BAY87-2243 is reported to be used for treating hepatitis B at present.
Disclosure of Invention
In order to solve the problems, the invention provides the application of a small molecule inhibitor BAY87-2243 in preparing a medicament for treating hepatitis B; the BAY87-2243 is a HIF-1 specific inhibitor.
Further, the drug is a drug that reduces the level of hepatitis b surface antigen production.
Further, the drug is a drug that reduces the level of hepatitis b e antigen production.
Further, the drug is a drug that inhibits transcription of hepatitis b virus.
Further, the medicament is a medicament for inhibiting the replication of hepatitis B virus DNA.
Further, the medicament is a medicament that reduces the expression level of hepatitis b virus cccDNA.
Furthermore, the medicine is a preparation prepared by taking a small molecular inhibitor BAY87-2243 as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
Still further, the formulation is an oral formulation; the oral preparation is granule, solution, pill, paste or tablet.
Experiments prove that the small molecular inhibitor BAY87-2243 can obviously inhibit HBV transcription and replication and effectively reduce the cccDNA expression level, so that the complete elimination of the virus carrying state of a hepatitis B patient becomes possible, the aim of antiviral treatment is finally achieved, and the application has practical popularization and application prospects.
It will be apparent that various other modifications, substitutions and alterations can be made in the present invention without departing from the basic technical concept of the invention as described above, according to the common technical knowledge and common practice in the field.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1 statistical data of the study on HBsAg/HBeAg secretion by BAY87-2243 treatment (A: effect of different concentrations of BAY87-2243 treatment on HepAD38 cytotoxicity and HBsAg secretion, B: effect of different concentrations of BAY87-2243 treatment on HepG2.2.15 cytotoxicity and HBsAg secretion, C: effect of different concentrations of BAY87-2243 treatment on HepAD38 cytotoxicity and HBeAg secretion, D: effect of different concentrations of BAY87-2243 treatment on HepG2.2.15 cytotoxicity and HBeAg secretion)
FIG. 2 statistical data of the effects of BAY87-2243 treatment on HBV transcription and replication levels and HBV cccDNA expression levels (A: the effect of BAY87-2243 treatment on HBV total RNA expression level in HepAD38 cells, B: the effect of BAY87-2243 treatment on HBVpgRNA expression level in HepAD38 cells, C: the effect of BAY87-2243 treatment on HBVDNA replication level in HepAD38 cells, D: the effect of BAY87-2243 treatment on HBVccc DNA expression level in HepAD38 cells) FIG. 3 in HBV-infected human primary hepatocytes, statistical data of the effects of BAY87-2243 treatment on HBV transcription and HBV replication levels and HBV cccDNA expression level (A: the effect of BAY87-2243 treatment on HBsAg secretion level, B: the effect of BAY87-2243 treatment on HBeAg secretion level, C: the effect of BAY87-2243 treatment on HBV total RNA expression level, B: the effect of BAY87-2243 treatment on HBgRNA expression level in HBeAg, and VpeAg expression level of HBgRNA in HBeAg
Detailed Description
Example 1 Effect of BAY87-2243 on secretion of HBsAg/HBeAg in hepatoma cells stably producing HBV
First, 8 × 10 4 One/well hepg2.215 and HepAD38 cells were seeded in 48-well plates, respectively. The next day after cell plating, cells were treated with different concentration gradients (0.01-100 nM) of BAY87-2243, respectively. After BAY87 treated the cells for 72h, cell Counting Kit-8 reagent (MedChemexpress, HY-K0301) was added to the 48-well plate, and the change in absorbance of the cells was detected by a multifunctional microplate reader at a wavelength of 450 nm. In addition, the cell supernatant was collected and the levels of HBsAg and HBeAg secreted in the cell supernatant were detected using a hepatitis B virus surface antigen diagnostic kit (enzyme-linked immunosorbent assay; shanghai Kehua, SI 0910113) and a hepatitis B virus E antigen detection kit (enzyme-linked immunosorbent assay; shanghai Kehua, 20163400144), respectively. The specific results of the microplate reader and the ELISA kit are shown in FIGS. 1A-D. From the results of the figures, it can be seen that: BAY87-2243 concentrations have a lesser effect on cytotoxicity at 100nM, and lower concentrations (<0.1 nM) of BAY87-2243 is effective in inhibiting secretion of HBsAg and HBeAg.
Example 2 Effect of BAY87-2243 on HBV transcription and replication levels and HBV cccDNA expression levels in HepAD38 cells
Will be 3X 10 5 One/well HepAD38 cells were seeded in 12-well plates, treated the next day with BAY87 at different concentration gradients (1, 2 or 4 nM) for 72h, then total intracellular RNA was extracted using Trizol reagent (Invitrogen, 15596026), and One-Step real RT-qPCR kit [ One Step TB
Figure BDA0003662523250000031
PrimeScript TM RT-PCR Kit II(Perfect Real Time),TaKaRa,RR086]Expression levels of HBV total RNA (FIG. 2A) and pgRNA (FIG. 2B) were measured in cells. From the results of the figures, it can be seen that: BAY87-2243 treatment with different concentrations can obviously reduce the expression level of HBV total RNA and pgRNA in cells, which indicates that BAY87-2243 can effectively inhibit HBV transcription in cells.
Will be 6X 10 5 The HepAD38 cells per well are inoculated in a 6-well plate, the next day, the cells are treated for 72h by BAY87-2243 with different concentration gradients (1, 2 or 4 nM), the cells are lysed, HBV DNA wrapped by nucleocapsid in the cells is extracted, and the influence of BAY87-2243 on the replication level of the HBV DNA in the cells is detected by a Southern blot method. The specific results are shown in FIG. 2C. From the graph results, it can be seen that: treatment with BAY87-2243 with different concentrations can obviously reduce the replication level of HBV DNA in cells, and the suggestion that BAY87-2243 can effectively inhibit the replication of HBV DNA in cells.
Will be 6X 10 5 HepAD38 cells were seeded in 6-well plates and treated the following day with varying concentration gradients (1, 2 or 4 nM) of BAY87-2243 for 96h. Then washing the cells with PBS 2 times, lysing the cells overnight, extracting DNA with phenol chloroform, subjecting the cccDNA obtained to an enzymatic cleavage reaction with T5 exonuclease, and performing Realtime qPCR (polymerase chain reaction)
Figure BDA0003662523250000032
Probe qPCR Master Mix, promega, a 6101) to detect HBV cccDNA expression levels in cells. The specific results are shown in FIG. 2D. From the graph results, it can be seen that: treatment of BAY87-2243 with different concentrations can obviously reduce the expression level of HBV cccDNA in cells, and the fact that BAY87-2243 can effectively reduce the expression level of HBVcccDNA in cells is suggested.
Example 3 investigation of the Effect of BAY87-2243 on HBV transcription and replication levels and HBV cccDNA expression levels in HBV-infected human primary hepatocytes
Commercial human primary cells were expanded at 5X 10 5 One/well was seeded in 12-well plates, and the next day after cell plating, cells were incubated with William's E complete medium containing HBV viral particles (MOI: 1000); 24h after HBV infection, cells were washed 3 times with PBS and then treated with BAY87-2243 at different concentration gradients (2 nM and 4 nM) for 6 consecutive days. Collecting cell supernatant, using (hepatitis B virus surface antigen diagnostic kit (enzyme linked immunosorbent assay) and hepatitis B virus E antigen detection kit (enzyme linked immunosorbent assay) to respectively collect cell supernatant and then detect the level of HBsAg and HBeAg secreted in the cell supernatant, and the specific results are shown in figures 3A-B, and the results of the figures show that BAY87-2243 can effectively inhibit the secretion of HBsAg and HBeAg.
Cells treated as in FIGS. 3A-B were washed 2 times with PBS, total RNA in the cells was extracted using Trizol reagent, and expression levels of HBV total RNA (FIG. 3C) and pgRNA (FIG. 3D) in the cells were measured using One-step simple RT-qPCR kit. From the results of the figures, it can be seen that: BAY87-2243 with different concentrations can obviously reduce the expression level of HBV total RNA and pgRNA in hepatocytes, which indicates that BAY87-2243 can effectively inhibit HBV transcription in primary human hepatocytes.
Cells treated as in FIGS. 3A-B were washed 2 times with PBS, lysed and nucleocapsid-encapsulated HBV DNA extracted from cells with phenol-chloroform and subjected to Realtime qPCR (TB)
Figure BDA0003662523250000042
Premix Ex Taq TM II (Tli RNaseH Plus), taKaRa, RR 820) test the effect of BAY87-2243 on the expression level of HBV DNA in cells. The specific results are shown in FIG. 3E. From the graph results, it can be seen that: BAY87-2243 treatment can obviously reduce the expression level of HBV DNA in cells, and the suggestion that BAY87-2243 can effectively inhibit the replication of HBVDNA in primary human hepatocytes.
The cells treated as in FIGS. 3A-B were washed 2 times with PBS, lysed and then the DNA was extracted with phenol chloroform, and finally the cccDNA obtained was cleaved with T5 exonuclease and processed with Realtime qPCR (R) (C)
Figure BDA0003662523250000041
Probe qPCR Master Mix, promega, a 6101) to detect HBV cccDNA expression levels in cells. The specific results are shown in FIG. 3F. From the graph results, it can be seen that: BAY87-2243 treatment can obviously reduce the expression level of HBV cccDNA in cells, and suggests that BAY87-2243 can effectively reduce the expression level of HBV cccDNA in human primary hepatocytes.
In conclusion, a series of experiments prove that the small molecular inhibitor BAY87-2243 can obviously inhibit HBV transcription and replication, effectively reduce cccDNA expression level, enable complete elimination of the virus carrying state of a hepatitis B patient to be possible, finally realize the aim of antiviral therapy, and has practical popularization and application prospects.

Claims (9)

1. The use of small molecule inhibitor BAY87-2243 in the preparation of medicine for treating hepatitis B; the BAY87-2243 is a HIF-1 specific inhibitor.
2. The use according to claim 1, wherein the medicament is a medicament for reducing the level of hepatitis b surface antigen production.
3. The use of claim 1, wherein the medicament is a medicament that reduces the level of hepatitis b e antigen production.
4. The use according to claim 1, wherein the medicament is a medicament for inhibiting transcription of hepatitis b virus.
5. The use according to claim 1, wherein the medicament is a medicament for inhibiting replication of hepatitis b virus DNA.
6. The use of claim 1, wherein the medicament is a medicament that reduces the expression level of hepatitis b virus cccDNA.
7. The use according to any one of claims 1 to 6, characterized in that the medicament is a preparation prepared by taking a small molecule inhibitor BAY87-2243 as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
8. Use according to claim 7, wherein the formulation is an oral formulation.
9. Use according to claim 8, characterized in that the oral formulation is a granule, solution, pill, paste or tablet.
CN202210576920.2A 2022-05-16 2022-05-25 Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B Active CN114886895B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022105292369 2022-05-16
CN202210529236 2022-05-16

Publications (2)

Publication Number Publication Date
CN114886895A CN114886895A (en) 2022-08-12
CN114886895B true CN114886895B (en) 2023-02-03

Family

ID=82726225

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210576920.2A Active CN114886895B (en) 2022-05-16 2022-05-25 Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B

Country Status (2)

Country Link
CN (1) CN114886895B (en)
WO (1) WO2023221361A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114886895B (en) * 2022-05-16 2023-02-03 重庆医科大学 Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022093770A1 (en) * 2020-10-27 2022-05-05 Memorial Sloan Kettering Cancer Center Combination therapy with pi3k-akt-mtor inhibitors and ferroptosis inducing agents to treat cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109381463A (en) * 2017-08-08 2019-02-26 复旦大学 Application of the tazarotene in preparation treatment hepatitis B virus infection drug
WO2019043193A1 (en) * 2017-09-01 2019-03-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) An inhibitor for use for preventing and/or treating an infection with hepatitis b virus
CN113337602A (en) * 2020-03-02 2021-09-03 苏州亚盛药业有限公司 Methods of treatment and biomarkers for MDM2 inhibitors
CN114886895B (en) * 2022-05-16 2023-02-03 重庆医科大学 Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022093770A1 (en) * 2020-10-27 2022-05-05 Memorial Sloan Kettering Cancer Center Combination therapy with pi3k-akt-mtor inhibitors and ferroptosis inducing agents to treat cancer

Also Published As

Publication number Publication date
CN114886895A (en) 2022-08-12
WO2023221361A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
CN114886895B (en) Application of small molecule inhibitor BAY87-2243 in preparing medicine for treating hepatitis B
EA036745B1 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
CN103458913A (en) Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases
CN114832023B (en) Application of herba Erodii seu Geranii effective component in treating or preventing viral hepatitis
CN109364074B (en) Application of 6-aminonicotinamide as effective component in preparing medicament for treating hepatitis B
CN114159572B (en) A pharmaceutical composition for the treatment of viral hepatitis
CN102631384B (en) Application of pomegranate in preparing medicament for treating or preventing hepatitis B virus infection
Furusawa et al. Therapeutic activity of pretazettine on Rauscher leukemia: combination of antiviral activity and cellular protein inhibition
CN102337263B (en) siRNA (Small interfering ribonucleic acid) capable of inhibiting expression of enterovirus 71 type gene, composition and application
CN114246847B (en) Application of chalcone compounds in treatment of coronavirus infection
CN114209844B (en) A pharmaceutical composition for treating viral hepatitis
CN115105519A (en) Pharmaceutical composition for treating hepatitis B and preparation method thereof
EP0643970A2 (en) 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide for use in medical treatment of humans
CN113304165B (en) Application of monomeric compound Ciliaoside A in preparation of hepatitis B treatment drug
CN105031613B (en) A kind of human beta-defensin 1 is preparing the application in treating or preventing hepatitis B virus infective medicament
CN115887452A (en) Use of rapamycin for treating or preventing hepatitis B
CN113502288A (en) Antisense oligonucleotide and application thereof in inhibiting new coronavirus
Yu et al. Strongylocentrotus nudus egg polysaccharide (SEP) suppresses HBV replication via activation of TLR4-induced immune pathway
CN109811030B (en) Application of antazoline hydrochloride derivative as HBV inhibitor
CN114515338B (en) Pharmaceutical composition for treating viral hepatitis
CN117281800A (en) Application of niclosamide in preparing medicine for treating hepatitis B
CN113975267B (en) Application of 6 alpha-hydroxyeyeurycommactone in preparation of anti-dengue virus drugs
CN115607560A (en) Pharmaceutical composition for treating hepatitis B and preparation method thereof
CN101317868B (en) Application of marsdenia tenacissima total saponin in preparing medicament for treating hepatitis B
CN114246859A (en) Application of andrographolide in preparing product for treating coronavirus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant